Latest Exocrine pancreatic insufficiency Stories
HAYWARD, Calif., Nov. 20, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Anthera to Form a New Subsidiary, Alkira Therapeutics, to Assume All Development Activities and Registration Activities as a Subsidiary of Anthera HAYWARD, Calif., July 14, 2014 /PRNewswire/
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
INDIANAPOLIS, Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S.
INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc.
ABBOTT PARK, Ill.., May 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that the U.S.
RARITAN, N.J., April 13 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S.